Wednesday, June 10, 2009
Elizabeth Laur, firstname.lastname@example.org
+1 414-276-2145 (MDS Secretariat)
MDS 13th International Congress Press Room (June 7-11):
Le Palais des Congres de Paris,
Room 212/213, Level 2, Hall Maillot, TEL: +33 (0)1 40 68 63 74
Pallidal Neurostimulation Shows Safety in Treatment of Idiopathic Dystonia
PARIS - A German multicenter study examining the efficacy and safety of pallidal neurostimulation in patients with primary generalized or segmental dystonia will be presented at The Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders.
Jens Volkmann, MD, PhD, and Andreas Kupsch, MD, PhD and colleagues from the Deep Brain-Stimulation for Dystonia Study Group, conducted a trial of 40 patients who were randomized to either sham or neurostimulation treatment.
The team discovered that efficacy of pallidal neurostimulation increased between six months and three years after surgery in patients with generalized dystonia, whereas patients with segmental dystonia tended to maintain a stable level of benefit after six months and three years. Dysarthria was the most common adverse effect in the long-term. Three years after surgery, pallidal neurostimulation continues to be effective and safe treatment option for patients.
Meeting attendees are gathered to learn the latest research findings and state-of-the-art treatment options for Movement Disorders, including Parkinson's disease. More than 3,900 physicians and medical professionals from 90 countries will be able to view over 1,700 scientific abstracts submitted by clinicians from around the world.
The Movement Disorder Society, an international society of over 3,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about the Movement Disorder Society, visit www.movementdisorders.org.